furamidine has been researched along with Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, MC; Ivanov, I; Kofsky-Wofford, SA; Lee, WC; Qian, K; Su, H; Yan, C; Yan, L; Zhao, X; Zheng, YG | 1 |
| Billoré, B; Boykin, DW; Dassi, C; David-Cordonnier, MH; Depauw, S; Farahat, AA; Figeac, M; Ismail, MA; Jambon, S; Kumar, A; Lambert, M; Marongiu, L; Mineva, E; Nhili, R; Paul, A; Paul-Constant, C; Peixoto, P; Stephens, CE; Sweat, DP; Wilson, WD | 1 |
2 other study(ies) available for furamidine and Leukemia
| Article | Year |
|---|---|
Diamidine compounds for selective inhibition of protein arginine methyltransferase 1.
Topics: Binding, Competitive; Catalytic Domain; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Cell Survival; Computer Simulation; Enzyme Inhibitors; Fluorescence Polarization; Humans; Immunoprecipitation; Kinetics; Leukemia; Models, Molecular; Pentamidine; Protein Binding; Protein-Arginine N-Methyltransferases; Repressor Proteins; Structure-Activity Relationship | 2014 |
Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model.
Topics: Cell Death; Cell Proliferation; DNA; Drug Design; Gene Expression; Heterocyclic Compounds; Homeodomain Proteins; Leukemia; Ligands; Models, Biological | 2019 |